A multinational research team led by Columbia University and the La Jolla Institute for Immunology has identified a novel viral target that could help combat the global resurgence of measles.
New images of one of the brain’s fastest-acting proteins—the kainate receptor—are providing critical clues that may lead to targeted therapies for epilepsy and other brain disorders.
Collaboration will investigate a system biology approach to identifying treatment options for patients with advanced gastrointestinal stromal tumors (GIST).
Transfusions of older blood could be harmful for some patients, leading Columbia researchers to recommend reducing the maximum blood storage limit from six to five weeks.
Columbia University researchers will participate in a seven-year NIH initiative to study the effect of a wide range of environmental factors on the health of children and adolescents.